Scynexis (SCYX) Convertible Debt (2019 - 2024)
Scynexis' (SCYX) quarterly Convertible Debt came in at $13.7 million in Q4 2024, up 12.58% on a YoY basis from $12.2 million in Q1 2024, and up 12.58% quarter-over-quarter from $12.2 million in Q4 2023.
Analysis
Scynexis (SCYX) Convertible Debt (2019 - 2024) Analysis & Trends
Scynexis (SCYX) has reported Convertible Debt for 6 consecutive years, with $13.7 million the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Convertible Debt rose 12.58% year-over-year to $13.7 million; the trailing twelve-month figure through Dec 2024 stood at $13.7 million (up 12.58% YoY), and the FY2024 full-year result was $13.7 million, up 12.58% from the prior year.
- Convertible Debt improved to $13.7 million in Q4 2024 per SCYX's latest filing, from $12.2 million in the prior quarter.
- Across five years, Convertible Debt topped out at $18.3 million in Q2 2020 and bottomed at $10.8 million in Q3 2021.
- Historically, Convertible Debt has averaged $12.4 million across 5 years, with a median of $11.6 million in 2023.
- The widest YoY moves for Convertible Debt: up 43.34% in 2020, down 39.33% in 2020.
- Over 5 years, Convertible Debt stood at $16.5 million in 2020, then retreated by 29.72% to $11.6 million in 2021, then dropped by 5.22% to $11.0 million in 2022, then grew by 10.53% to $12.2 million in 2023, then gained by 12.58% to $13.7 million in 2024.
- According to Business Quant data, Convertible Debt over the past three periods registered $13.7 million, $12.2 million, and $11.8 million for Q4 2024, Q4 2023, and Q3 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 13.69 Mn |
| Dec 31, 2023 | 12.16 Mn |
| Sep 30, 2023 | 11.81 Mn |
| Jun 30, 2023 | 11.63 Mn |
| Mar 31, 2023 | 11.41 Mn |
| Dec 31, 2022 | 11.00 Mn |
| Sep 30, 2022 | 11.03 Mn |
| Jun 30, 2022 | 10.82 Mn |
| Mar 31, 2022 | 10.82 Mn |
| Dec 31, 2021 | 11.61 Mn |
| Sep 30, 2021 | 10.81 Mn |
| Jun 30, 2021 | 12.00 Mn |
| Mar 31, 2021 | 12.23 Mn |
| Dec 31, 2020 | 16.52 Mn |
| Sep 30, 2020 | 13.28 Mn |
| Jun 30, 2020 | 18.25 Mn |
| Mar 31, 2020 | 11.10 Mn |
| Dec 31, 2019 | 11.52 Mn |
| Sep 30, 2019 | 12.57 Mn |
| Jun 30, 2019 | 14.59 Mn |